Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
5/4/2006
 
First Published:
8/24/2004
1.
Phase III Randomized Evaluation Of Convection Enhanced Delivery Of IL13-PE38QQR (Interleukin-13 PE38QQR Immunotoxin) Compared To GliadelĀ® Wafer (Polifeprosan 20 With Carmustine Implant) In Glioblastoma Multiforme Patients At First Recurrence
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
NEOPHARM-IL13PEI-301
UCLA-040305101, NEOPHARM-IL13PEI-301-R01, PRECISE, NCT00076986
Last Modified:
3/14/2005
 
First Published:
9/1/2000
2.
Phase I/II Study of Interstitial Interleukin-13 PE38QQR Immunotoxin in Patients With Malignant Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
NCI, Pharmaceutical / Industry
NABTT-9903
JHOC-NABTT-9903, NEOPHARM-TS-G1-TI4, NEOPHARM-IL13PEI-001-R03, NCT00006268
Last Modified:
9/18/2007
 
First Published:
12/21/2002
3.
Phase I/II Study of Peritumoral IL13-PE38QQR in Pediatric Patients With Recurrent Malignant Gliomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
3 to 21
NCI, Pharmaceutical / Industry
PBTC-011C
NEOPHARM-IL13PEI-151, NCI-5930, NCT00053040, PBTC-011
Last Modified:
3/28/2007
 
First Published:
5/1/2002
4.
Phase I Study of Continuous Intracerebral Infusion of Interleukin-13 PE38QQR Immunotoxin Before and After Second Resection in Patients With Recurrent Resectable Supratentorial Malignant Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
MSKCC-01141
NEOPHARM-IL13PEI-002-R01, NCI-G02-2066, NCT00036972
5.
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Diagnostic, Treatment
Closed
18 and over
Pharmaceutical / Industry
IL13PEI-105
NCT00064779
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute